Revenue has contracted significantly alongside gross margin compression, which fell from a peak of 62.5% in 2024Q1 to 29.2% in 2026Q1.
| Sales/Revenue | 22.53M | 27.48M | 41.81M | 24.41M | 44.53M | 27.04M | 9.58M | 27.26M | 26.43M | 20.59M | 14.81M | 10.27M | 5.81M |
| Revenue Growth % | -42.94% | -34.26% | 71.31% | -45.2% | 64.68% | 182.36% | -64.87% | 3.16% | 28.36% | 39% | 44.17% | 76.81% | - |
| Cost of Goods Sold | 14.03M | 15.62M | 17.38M | 10.35M | 14.9M | 10.05M | 4.33M | 9.71M | 9.52M | 6.79M | 4.97M | 3.7M | 2.05M |
| COGS % of Revenue | - | 56.82% | 41.56% | 42.39% | 33.47% | 37.18% | 45.19% | 35.6% | 36.01% | 32.97% | 33.52% | 36% | 35.37% |
| Gross Profit | 8.51M | 11.87M | 24.43M | 14.06M | 29.63M | 16.99M | 5.25M | 17.56M | 16.91M | 13.8M | 9.85M | 6.57M | 3.76M |
| Gross Margin % | 37.75% | 43.18% | 58.44% | 57.61% | 66.53% | 62.82% | 54.81% | 64.4% | 63.99% | 67.03% | 66.48% | 64% | 64.63% |
| Gross Profit Growth % | - | -51.43% | 73.76% | -52.54% | 74.41% | 223.64% | -70.1% | 3.82% | 22.54% | 40.16% | 49.76% | 75.07% | - |
| Operating Expenses | 20.52M | 22.17M | 16.34M | 14.44M | 14.8M | 12.87M | 13.48M | 19.53M | 18.92M | 17.52M | 10.21M | 6.8M | 7.44M |
| OpEx % of Revenue | - | 80.69% | 39.09% | 59.18% | 33.23% | 47.59% | 140.79% | 71.62% | 71.58% | 85.09% | 68.93% | 66.15% | 127.98% |
| Selling, General & Admin | 13.76M | 14.4M | 12.13M | 10.76M | 11.34M | 9.43M | 9.32M | 13.11M | 12.66M | 12.03M | 8.38M | 5.33M | 5.86M |
| SG&A % of Revenue | - | 52.38% | 29% | 44.11% | 25.46% | 34.88% | 97.37% | 48.08% | 47.89% | 58.42% | 56.61% | 51.87% | 100.84% |
| Research & Development | 6.76M | 7.78M | 4.22M | 3.68M | 3.46M | 3.44M | 4.16M | 6.42M | 6.26M | 5.49M | 1.82M | 1.47M | 1.58M |
| R&D % of Revenue | - | 28.3% | 10.08% | 15.07% | 7.77% | 12.71% | 43.42% | 23.54% | 23.69% | 26.67% | 12.32% | 14.28% | 27.14% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -12.02M | -10.31M | 8.09M | -382K | 14.83M | 4.12M | -8.23M | -1.97M | -2.01M | -3.72M | -363.12K | -221.26K | -3.68M |
| Operating Margin % | -53.34% | -37.5% | 19.35% | -1.57% | 33.3% | 15.24% | -85.98% | -7.22% | -7.59% | -18.06% | -2.45% | -2.15% | -63.34% |
| Operating Income Growth % | - | -227.4% | 2217.8% | -102.58% | 259.98% | 150.04% | -318.33% | 1.85% | 46.06% | -923.75% | -64.12% | 93.99% | - |
| EBITDA | -11.66M | -9.92M | 8.52M | 79K | 15.34M | 4.73M | -7.51M | -1.42M | -1.35M | -3.33M | -25.54K | 94.34K | -3.41M |
| EBITDA Margin % | -51.74% | -36.1% | 20.38% | 0.32% | 34.45% | 17.5% | -78.44% | -5.22% | -5.1% | -16.17% | -0.17% | 0.92% | -58.65% |
| EBITDA Growth % | -486.57% | -216.42% | 10687.34% | -99.48% | 224.11% | 163.01% | -428.06% | -5.6% | 59.54% | -12938.55% | -127.07% | 102.77% | - |
| D&A (Non-Cash Add-back) | 360K | 386K | 432K | 461K | 509K | 613K | 722K | 545.72K | 658.25K | 387.92K | 337.58K | 315.6K | 272.65K |
| EBIT | -8.93M | -10.31M | 8.09M | -382K | 14.83M | 4.12M | -6.82M | -1.7M | -1.87M | -3.64M | -324.58K | -219.48K | -3.68M |
| Net Interest Income | 706K | 683K | 932K | 992K | 380K | 1K | 52K | 268.29K | -17.41K | 6.93K | 16.67K | -16.01K | -19.21K |
| Interest Income | 706K | 683K | 932K | 992K | 382K | 2K | 66K | 268.29K | 139.28K | 75.81K | 38.54K | 1.78K | 820 |
| Interest Expense | 0 | 0 | 0 | 0 | 2K | 1K | 14K | 0 | 156.69K | 68.88K | 21.87K | 17.79K | 20.03K |
| Other Income/Expense | 624K | 683K | 932K | 1.03M | 13.16M | -1K | 1.4M | 268.29K | -17.41K | 6.93K | 16.67K | -16.01K | -19.21K |
| Pretax Income | -11.39M | -9.62M | 9.02M | 652K | 27.99M | 4.12M | -6.84M | -1.7M | -2.02M | -3.71M | -346.45K | -237.27K | -3.7M |
| Pretax Margin % | -50.57% | -35.02% | 21.58% | 2.67% | 62.85% | 15.23% | -71.38% | -6.24% | -7.65% | -18.02% | -2.34% | -2.31% | -63.67% |
| Income Tax | -3.62M | -1.91M | 2.38M | 167K | 3.75M | 0 | 0 | 0 | 0 | 0 | 0 | 1.78K | 820 |
| Effective Tax Rate % | 31.79% | 19.79% | 26.32% | 25.61% | 13.38% | 0% | 0% | 0% | 0% | 0% | 0% | -0.75% | -0.02% |
| Net Income | -7.77M | -7.72M | 6.65M | 485K | 24.24M | 4.12M | -6.84M | -1.7M | -2.02M | -3.71M | -346.45K | -237.27K | -3.7M |
| Net Margin % | -34.5% | -28.09% | 15.9% | 1.99% | 54.44% | 15.23% | -71.38% | -6.24% | -7.65% | -18.02% | -2.34% | -2.31% | -63.67% |
| Net Income Growth % | -531.59% | -216.13% | 1270.52% | -98% | 488.59% | 160.25% | -302.12% | 15.96% | 45.49% | -971.02% | -46.02% | 93.59% | - |
| Net Income (Continuing) | -7.77M | -7.72M | 6.65M | 485K | 24.24M | 4.12M | -6.84M | -1.7M | -2.02M | -3.71M | -346.45K | -237.27K | -3.7M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.47 | -0.47 | 0.41 | 0.03 | 1.46 | 0.25 | -0.42 | -0.07 | -0.14 | -0.28 | -0.03 | -0.02 | -0.37 |
| EPS Growth % | -540.47% | -214.63% | 1275.84% | -97.96% | 484% | 159.52% | -490.72% | 49.21% | 50% | -872.22% | -30.91% | 94.05% | - |
| EPS (Basic) | - | -0.47 | 0.41 | 0.03 | 1.47 | 0.25 | -0.42 | -0.07 | -0.14 | -0.28 | -0.03 | -0.02 | -0.37 |
| Diluted Shares Outstanding | 16.46M | 16.33M | 16.36M | 16.27M | 16.62M | 16.5M | 16.43M | 16.23M | 14.12M | 13.24M | 12.03M | 10.78M | 9.89M |
| Basic Shares Outstanding | 16.46M | 16.33M | 16.31M | 16.26M | 16.48M | 16.48M | 16.43M | 16.23M | 14.12M | 13.24M | 12.03M | 10.78M | 9.88M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - |
Reimbursement and sales volatility
As reported in recent financial filings, Sensus Healthcare experienced a severe revenue decline, with top-line figures falling to $3.4M in 2026Q1 from $12.6M in 2023Q4, representing a sustained period of negative growth that suggests significant challenges in maintaining the company's capital equipment sales cycle.
The consistent quarter-over-quarter revenue decay indicates that the company's primary sales funnel for SRT-100 units is facing substantial friction. This trend suggests that the high-ticket nature of the equipment may be increasingly sensitive to the current macroeconomic environment and private practice capital expenditure constraints.
Based on the company's quarterly income statements, gross margins have compressed from a peak of 62.5% in 2024Q1 to 29.2% in 2026Q1, indicating that Sensus is struggling to maintain pricing power or manage rising component costs amidst a shrinking installed base of active medical devices.
The sharp deterioration in gross margin suggests that the company may be forced to offer deeper discounts to move inventory or that the mix of revenue has shifted toward lower-margin service offerings. Investors should monitor whether this margin compression is structural or a temporary reaction to competitive pricing pressures.
According to the provided income statement data, Sensus has transitioned from an operating profit of $5.6M in 2023Q4 to an operating loss of $4.4M in 2026Q1, demonstrating a clear case of operating deleveraging where fixed costs are outpacing the company's ability to generate gross profit.
The inability to scale SG&A and R&D expenses relative to declining revenue suggests that the current cost structure is misaligned with the company's reduced operational scale. This trend implies that without a significant revenue inflection, the company may continue to burn through its cash reserves to sustain its current overhead.
While the company maintains a clean balance sheet with minimal debt, the persistent negative net income, which reached -$2.6M in 2026Q1, warrants further investigation into whether the current business model can achieve profitability before the existing cash cushion is exhausted by ongoing operational losses.
Short-term observers may focus on the risk that the company's reliance on capital equipment sales is fundamentally incompatible with the current market environment. The lack of a clear path to positive operating margins suggests that the company's long-term viability may depend on a pivot toward a more predictable, recurring revenue model.
Quick answers to the most common questions about buying SRTS stock.
For fiscal year 2025, Sensus Healthcare, Inc. (SRTS) reported total revenue of $27.5M. This represents a 373.0% increase compared to $5.8M in 2014.
Sensus Healthcare, Inc. (SRTS) reported a net loss of $7.7M for the fiscal year ending 2025.
Sensus Healthcare, Inc. (SRTS) reported an operating income of $-10.3M, resulting in an operating profit margin of -37.5%. This margin reflects the operational efficiency of the business before interest and taxes.
Sensus Healthcare, Inc. (SRTS) generated $11.9M in gross profit for the year, representing a gross profit margin of 43.2%. This demonstrates the company's core pricing power and production efficiency.